USFDA

COVID Second Wave and Us – Blog Post #431 by Asrar Qureshi

Posted on January 11, 2021January 11, 2021
No comments
byAsrar Qureshi

Dear Colleagues! This is Pharma Veterans Blog Post #431. Pharma Veterans welcomes sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published…

View Post

4 min

Tender Spots of Pharma Industry V – Blog Post #390 by Asrar Qureshi

Posted on October 5, 2020October 5, 2020
No comments
byAsrar Qureshi

Dear Colleagues! This is Pharma Veterans Blog Post #390. Pharma Veterans welcomes sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published…

View Post

4 min

Tender Spots of Pharma Industry III – Blog Post #388 by Asrar Qureshi

Posted on September 30, 2020September 30, 2020
No comments
byAsrar Qureshi

Dear Colleagues! This is Pharma Veterans Blog Post #388. Pharma Veterans welcomes sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published…

The Case of ‘Ja’alee’ (spurious) Drugs – Pharma Industry in Pakistan and Neighboring Countries – Blog Post #285 by Asrar Qureshi

Dear Colleagues! This is Pharma Veterans Blog Post #285. Pharma Veterans shares the wealth of knowledge and wisdom of Veterans for the benefit of Community at large. Pharma Veterans Blog is…

COVID Second Wave and Us – Blog Post #431 by Asrar Qureshi

Tender Spots of Pharma Industry V – Blog Post #390 by Asrar Qureshi

Tender Spots of Pharma Industry III – Blog Post #388 by Asrar Qureshi

The Case of ‘Ja’alee’ (spurious) Drugs – Pharma Industry in Pakistan and Neighboring Countries – Blog Post #285 by Asrar Qureshi

New Milestones in Drug Development – Blog Post by Asrar Qureshi

Coronary Heart Disease and Statins Controversy (Part VI) – Blog Post by Asrar Qureshi

Coronary Heart Disease and Statins Controversy (Part V) – Blog Post by Asrar Qureshi

Coronary Heart Disease & Statins Controversy (Part III) – Blog Post by Asrar Qureshi

Fluoroquinolones Safety Concerns and Warnings (Part I) – Blog Post by Asrar Qureshi